Articles Referencing VVUS

Unique Investor Kyle Bass Unloads Five

5/29/2013, 6:26 pm from GuruFocus in Investing

Investor J. Kyle Bass is truly unique. What differentiates the principal of Hayman Advisors from other super investors? He's politically connected but reportedly does not vote and does... Read >>

ARNA Sheds Light on Belviq Launch - Analyst Blog

5/9/2013, 4:24 pm from Zacks.com in Investing, Business, Stocks

Arena Pharmaceuticals Inc. ( ARNA ) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances... Read >>

Benzinga Market Primer: Wednesday, May 8

5/8/2013, 6:27 am from Benzinga in Investing, Bonds, Commodities, Futures, International

Futures Flat On Strong Chinese Trade Data U.S. equity futures traded flat in early pre-market trade despite China reporting a rise in its trade balance in April. China reported that its trade... Read >>

CHMP Backs VIVUS' Spedra - Analyst Blog

4/30/2013, 4:48 pm from Zacks.com in Investing, Business, Stocks

VIVUS, Inc. ( VVUS ) recently announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its drug, Spedra... Read >>

Merck Likely to Beat 1Q Earnings - Analyst Blog

4/29/2013, 4:50 pm from Zacks.com in Investing, Business, Earnings, Stocks

We expect Merck & Co. Inc. ( MRK ) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on May 1, 2013. Why a Likely Positive Surprise?... Read >>

Pfizer Likely to Report In Line Earnings - Analyst Blog

4/29/2013, 4:50 pm from Zacks.com in Investing, Business, Earnings, Stocks

We expect Pfizer ( PFE ) to report in line first-quarter 2013 results before the opening bell on Apr 30, 2013. Factors at Play for 1Q We expect Pfizer to struggle to post meaningful... Read >>

Will Eli Lilly Beat Earnings in 1Q? - Analyst Blog

4/23/2013, 5:11 pm from Zacks.com in Investing, Business, Earnings, Stocks

We expect Eli Lilly and Company ( LLY ) to beat earnings expectations when it reports first-quarter 2013 results before the opening bell on Apr 24, 2013. Why a Likely Positive Surprise? ... Read >>

Will Amgen Beat Earnings? - Analyst Blog

4/22/2013, 5:11 pm from Zacks.com in Investing, Business, Earnings, Stocks

We expect Amgen Inc. ( AMGN ) to beat earnings expectations when it reports first-quarter 2013 results after the closing bell on Apr 23, 2013. Why a Likely Positive Surprise? Our... Read >>

Forest Labs Likely to Miss 4Q Earnings - Analyst Blog

4/22/2013, 12:11 pm from Zacks.com in Investing, Business, Earnings, Stocks

We expect Forest Laboratories Inc. ( FRX ) to miss earnings expectations when it reports fourth-quarter fiscal 2013 results on Apr 23, before the opening bell. Forest Labs' fiscal year ends... Read >>

Expanded Access for VIVUS' Qsymia - Analyst Blog

4/18/2013, 7:10 pm from Zacks.com in Investing, Business, Stocks

VIVUS, Inc. ( VVUS ) recently announced that the amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) of its obesity drug, Qsymia (phentermine and topiramate... Read >>

Vivus Sees a Rare Jump in Near-Term Call Volume

4/17/2013, 4:20 pm from Minyanville in Investing, Options

Vivus ( VVUS ) was trending higher on Tuesday, after the Food and Drug Administration (FDA) granted the firm approval to sell its weight-loss drug, Qsymia, in retail pharmacies. As a result,... Read >>

ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog

4/3/2013, 4:19 pm from Zacks.com in Investing, Business, Stocks

Arena Pharmaceuticals, Inc. ( ARNA ) recently announced that Eisai Laboratories S. de R.L. de C.V, a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for... Read >>

Vivus Opts for Royalty Financing - Analyst Blog

4/2/2013, 7:21 pm from Zacks.com in Investing, Business, Stocks

Vivus, Inc. ( VVUS ) recently announced that it has entered into an agreement with a Pharmakon Advisors managed investment fund for a $110 million non-equity financing. Vivus will initially... Read >>

Loss at OREX Narrower than Expected - Analyst Blog

3/14/2013, 5:45 pm from Zacks.com in Investing, Business, Stocks

Orexigen Therapeutics, Inc. ( OREX ) reported a net loss of 41 cents per share in the fourth quarter of 2012, much wider than the year-ago loss of 9 cents but 4 cents narrower than the... Read >>

Arena Cuts Loss, Misses Estimates - Analyst Blog

3/8/2013, 2:43 pm from Zacks.com in Investing, Business, Stocks

Arena Pharmaceuticals Inc.'s ( ARNA ) loss (excluding special items) of 10 cents per share in the fourth quarter of 2012 was narrower than the year-ago loss of 16 cents per share.  The... Read >>